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Abstract. Glutathione-S-transferases (GSTs) are a super-
family of phase II metabolizing enzymes that catalyse the
detoxification of a large range of endogenous and exogenous
toxic compounds, playing an important role in protecting
cells against damage, through glutathione conjugation with
electrophilic substances. Polymorphic variation in these
enzymes that affect its activity seems to be related to
individual susceptibility to various human diseases, including
cancer. Of the GST super-family, the alpha class GSTs have
commonly been described as one of the most versatile class,
since it is responsible for detoxification of compounds such as
bilirubin, bile acids and penicillin, thyroid and steroid
hormones, allowing its solubilization and storage in the liver.
Among the alpha class, GSTA1 and GSTA2 isoforms are the
most widely expressed in human tissues. Additionally, these
enzymes can catalyse conjugation of the nitrogen mustard
group of alkylating anticancer drugs, some heterocyclic
amines and ·,ß-unsaturated aldehydes. Since some risk
factors for increased breast cancer risk could be related to
high production of reactive oxygen species during the
metabolism of estrogens by catechol estrogens, or to the
exposure to genotoxic compounds, and some of these toxic
compounds are usually metabolized by GSTA2, we carried
out a hospital based case-control study in a Caucasian
Portuguese population (291 breast cancer patients without
familiar history of breast cancer and 547 controls matched
for age, sex and ethnicity) in order to evaluate the potential
modifying role of three non-synonymous polymorphisms in
the GSTA2 gene (P110S Ex 5+56C>T;, rs2234951; S112T
Ex5+63G>C, rs2180314 and E210A Ex7+83A>C, rs6577)
on the individual susceptibility to breast cancer. Our data
show that the studied polymorphisms are in strong linkage
disequilibrium, but no association was observed between
individual GSTA2 polymorphisms and haplotypes and
individual susceptibility to breast cancer.
Introduction
Breast cancer is the main type of female cancer (about 182,460
new cases are estimated by the American Cancer Society for
2008, in the USA) and the second leading cause of cancer
death in women (1). However, the etiology of this disease
remains elusive, even though it is known that for a substantial
fraction of breast cancer cases, the age at the first child's
birth, parity, menopausal age (i.e. reproductive and hormonal
factors) and family history, are well-established risk factors.
The hereditary fraction of this pathology accounts for
5-10% of all breast cancer cases (2,3), with BRCA1 and
BRCA2 having been identified as the two main susceptibility
genes from familial linkage studies (3). Even though mutations
in these genes are highly associated with inherited predis-
position, somatic mutations in these genes are rare in sporadic
breast cancer cases.
The majority of the risk factors, mainly related to sporadic
cases, point to an association with prolonged exposure to
increased levels of estrogens (4,5). Several epidemiological
studies have been published showing that circulating estrogens
may contribute to an increased risk of breast cancer. Further-
more, during the metabolism of estrogen some carcinogenic
metabolites can be produced, such as cathecol estrogens (6-8).
These metabolites could be responsible for an increased
production of Reactive Oxygen Species (ROS), leading to
disruption of cellular redox homeostasis (7,8) and DNA
lesions. It is postulated that the genotoxic consequences of the
oxidative estrogen metabolism pathway is mitigated by
conjugation reactions of the metabolites with phase II enzymes
(8). Several enzymes are involved in the oxidative metabolism
and conjugation of estrogens (7), suggesting a potential
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involvement of the polymorphic forms of their genes in
breast cancer susceptibility. 
One of the enzymatic families involved in Phase II
metabolism (6,7,9,10) is the highly polymorphic Glutathione
S-Transferase (GSTs) super family which is responsible for
carcinogen detoxification by conjugation with reduced
glutathione (GSH) of numerous reactive metabolites, including
by-products of oxidative stress (11) and metabolites generated
through the oxidative estrogen metabolism pathway (6,8).
Some of these metabolites include estrogen quinones that
undergo conjugation with GSH through the catalytic action
of GSTP1. The formation of GSH-estrogen conjugates would
reduce the level of estrogen quinones and thereby lower the
potential for DNA damage (8).
The alpha class GSTs are strongly expressed in liver,
kidney and adrenal tissue, and have commonly been described
as one of the most versatile GST families, since it is responsible
for GSH conjugation of compounds such as bilirubin, bile
acids and penicillin, thyroid and steroid hormones, allowing
their solubilization and storage in the liver (12). Additionally,
the conjugation of the nitrogen mustard group of alkylating
anticancer drugs, of some heterocyclic amines and ·,ß-unsatu-
rated aldehydes also leads to detoxification (12,13). GSTA1
and GSTA2 are the most expressed alpha GSTs enzymes in
the liver (14,15), but they are also expressed in the human
breast (15). There are few epidemiological studies relating
the role of polymorphic alpha class GST in cancer suscepti-
bility (16,17), especially in breast cancer (15). Since the
Alpha family is involved in a wide range of roles that include
steroid biosynthesis and providing protection against
alkylating agents, polymorphic variations in these genes
could be responsible for physiological consequences that
could alter the susceptibility to disease and drug response
(12). Two members of this class, GSTA1 and GSTA2 (usually
co-expressed), catalyze the GSH conjugation of a wide
variety of electrophiles, possess glutathione-dependent steroid
isomerase activity, and glutathione-dependent peroxidase
activity (14). The GSTA2 gene is believed to represent a major
line of defense against oxidative stress (18).
To date, some epidemiological studies, regarding breast
cancer susceptibility, have been carried out focusing on
several polymorphic families of GSTs, mostly the GSTT1,
GSTM1 and GSTP1 genes (6,19-26). Other GST families
have been less studied, and there is a scarcity of results
regarding the influence of the alpha class with breast cancer
susceptibility. Since the GSTA2 gene is involved in the
detoxification of metabolites associated with an increase risk
to breast cancer, we carried out a hospital based case-control
study in a Caucasian Portuguese population in order to
evaluate the potential modifying role of the non-synonymous
polymorphisms in the GSTA2 gene (P110S Ex 5+56C>T;,
rs2234951; S112T Ex5+63G>C, rs2180314 and E210A
Ex7+83A>C, rs6577) on the individual susceptibility to
breast cancer.
Materials and methods
Study subjects. This study includes 291 Caucasian breast
cancer female patients, recruited at São Francisco Xavier
Hospital (Department of Laboratory Medicine), without
previous history of neoplasic disease, thyroid pathology and
blood transfusions. Histological diagnosis was confirmed in
all the cases. The control population (n=547) matched for sex
and ethnicity, with no previous or concurrent malignant
disease, was recruited at the same hospital where they were
observed for non-malignant pathology. The anonymity of the
patients and control population was guaranteed, and all
studies were conducted with the written informed consent of
all the individuals involved, obtained prior to blood with-
drawal. Information on demographic characteristics, family
history of cancer, lifestyle habits (e.g. smoking, alcohol
drinking) was collected using a questionnaire administered
by trained interviewers. Former smokers were defined as those
who gave up smoking two years before cancer diagnosis or
two years before the inclusion date as corresponding matched
case. The response rate was higher than 95% for cases and
controls.
DNA extraction. Blood samples of all patients and controls
were collected into 10 ml heparinized tubes and stored at -20˚C
until use. Genomic DNA was obtained from 250 μl of whole
blood using a commercially available kit according to the
manufacturer instructions (QIAamp DNA extraction kit;
Qiagen, Hilden, Germany). Each DNA sample was stored at
-20˚C until analysis.
Genotyping GSTA2 P110S, S112T and E210A gene polymor-
phisms. The genotyping of E210A polymorphism was
determined by PCR-RFLP. The primers and PCR conditions
for the polymorphic sites of this SNP are shown in Table I.
This polymorphism results in either gain or loss of restriction
sites, which therefore allowed the wild-type and variant
alleles to be discriminated by RFLP after appropriate
restriction enzyme digestion. After amplification, 10 μl of
each PCR products were digested with appropriate restriction
enzymes and eletrophoresed in 4% agarose gel with ethidium
bromide (0.5 μg/ml) for visualization under ultraviolet light.
The expected product for each genotype of the tested SNP is
shown in Table I. All the genotype determinations were
carried out twice in independent experiments and inconclusive
samples were reanalysed.
The P110S and S112T polymorphisms were genotyped
by real-time PCR (AB7300) using TaqMan SNP Genotyping
Assays from Applied Biosystems (ABI Assays reference:
C_12027714_50 and C_22275149_30, respectively) according
to the manufacturer's instructions. To carry out the allelic
discrimination the DNA samples were quantified by PicoGreen
dsDNA Quantification Reagent (Molecular Probes, Eugene,
OR, USA) according to the manufacturer's recommendations.
Statistical analysis. Genotypic frequencies and the analysis
of Hardy-Weinberg frequencies for the different polymor-
phisms studied, in the control and patients populations, were
carried out using Mendel software (27).
The degree of linkage disequilibrium between the different
SNPs expressed as D', and the haplotype estimation for the
combination of the different SNPs studied were calculated
using SNPStats software (28).
The ¯2 test was used to evaluate the differences in geno-
type frequency, smoking status and alcohol consumption
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distributions between cases and controls. The Kolmogorov-
Smirnov test was used in order to verify the normality of the
continuous variables (e.g. age) and the Levene test was used
to analyse the homogeneity of variances.
The crude and adjusted odds ratio (OR) and the corres-
ponding 95% confidence intervals (CI) were calculated using
unconditional multiple logistic regression. The model for
adjusted OR included terms for age at diagnosis (≤30, 31-49,
50-69 and ≥70 years), the lower age group being the reference
class; alcohol consumption (never, social and regular drinkers)
non-drinkers being the reference group, and smoking habits
(smokers/non smokers), non-smokers being the reference
group. All analyses were performed with an SPSS statistical
package (version 15.0) (SPSS Inc. Chicago, IL).
Results
Two-hundred and ninety-one breast cancer patients and 547
age-matched controls in this Portuguese case-control study
were included. The main characteristics (age, smoking and
alcohol habits) for both populations are shown in Table II. No
significant differences for age and smoking habits were found
between cases and controls. However, alcohol drinkers are
more prevalent among breast cancer patients than in the
control population.
We included in this study 3 SNPs present in the GSTA2
gene (P110S, S112T and E210A), all non-synonymous. All
the SNPs are in Hardy-Weinberg equilibrium and in Table III
are depicted the Minor Allele Frequency (MAF), and genotype
frequencies in both populations. MAF values obtained were
in accordance with the ones reported in the HapMap project
(http://www.hapmap.org/). The data available in the literature
in Caucasian populations, the genotype frequencies for the
GSTA2 S112T polymorphism and the values reported in
these studies are ambiguous, two of them are in agreement
with the data obtained in this study (16,29), while further two
studies report different frequencies (17,30). The SNP
frequencies in control and cancer population are not
significantly different and the crude and adjusted ORs
associated with each polymorphism are not significantly
different (Table III), suggesting that these polymorphisms are
not associated with breast cancer susceptibility. The ORs
associated with the different SNPs studied after stratification
for different breast cancer status, that could be relevant as
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Table I. PCR-RFLP details for GSTA2 (E210A) polymorphism.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GSTA2 Primer sequence Temp. PCR Effect on enzyme Patterns after
(˚C) product restriction site enzyme restriction
(bp) enzyme digestion
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Forward 5'-CCAAggAAgCCTCCCATgCATg-3' AA: 163bp;
E210A 62 163 A➝C creat one PaeI AC: 163, 140, 23bp; 
Reverse 5'-gCTTCACAACAggCACAATCAACAC-3' restriction site CC: 140, 23bp
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table II. General characteristics of breast cancer cases (n=291) and control (n=547) populations studied.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Characteristics Cases n (%) Controls n (%) P-valued
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Agea,b
≤30 1 (0.3) 2 (0.4)
31-49 68 (23.4) 120 (21.9) 0.921c
50-69 161 (55.3) 300 (54.8)
≥70 61 (21.0) 125 (22.9)
Smoking habits
Never and former 254 (87.9) 490 (91.6)
Current 35 (12.1) 45 (8.4) 0.087c
Missing 2 12
Alcohol habits
Never 221 (76.2) 441 (82.6)
Social 25 (8.6) 59 (11.0) <0.0001c
Regular 44 (15.2) 34 (6.4)
Missing 1 13
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aAge of cases at diagnosis; bage of control population at the time of diagnosis for the matched case; ccases vs. control group; dsee Materials
and methods.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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potential risk factors (i.e. breast feeding, menopausal age,
menarche age, parity, age at first full-term pregnancy), were
undertaken and did not reveal any potential association with
disease either (data not shown). The linkage disequilibrium
analysis was determined using SNPStats software, and
demonstrates that all SNPs evaluated in this study are in
linkage disequilibrium, measured by D' values as depicted in
Table IV.
The combination of the different alleles of the GSTA2
gene could potentially generate eight different haplotypes,
but haplotype estimation with the data obtained in our study
only reveal the existence of six different haplotypes (Table V),
four of them were previously described by Tetlow et al in
Australian, Bantu African, Creole African and Chinese
populations (12,13). From the different haplotypes generated
by the GSTA2 non-synonymous polymorphism two of them
(P110; S112; E210 and P110; T112; E210) (see Table V)
have a cumulative frequency higher than 90% in both popu-
lations studied, and each one with a similar frequency in both
populations. Accordingly, the data obtained concerning the
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Table III. Genotype distribution and breast cancer risk to the polymorphisms studied (GSTA2 P110S, S112T and E210A) in
cases and control population.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MAF




CC 265 (91.7) 505 (92.8) 1 (Reference) 1 (Reference)
CT 24 (8.3) 39 (7.2) 1.173 (0.690-1.992) 1.218 (0.705-2.104)




GG 92 (31.8) 155 (28.5) 1 (Reference) 1 (Reference)
GC 146 (50.5) 280 (51.6) 0.878 (0.634-1.218) 0.873 (0.625-1.219)
C: 0.4291±0.0206 C: 0.4567±0.0151
CC 51 (17.6) 108 (19.9) 0.796 (0.522-1.212) 0.770 (0.501-1.184)
Missing 2 4 - -
E210A (Ex7+83A>C)
AA 257 (88.6) 485 (88.7) 1 (Reference) 1 (Reference)
AC 33 (11.4) 61 (11.2) 1.017 (0.649-1.594) 1.008 (0.635-1.601)
CC 0 (0) 1 (0.2) C: 0.0569±0.0096 C: 0.0576±0.007 ND ND
AC + CC 33 62 1.001 (0.639-1.567) 0.989 (0.623-1.569)
Missing - - - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aORs were adjusted for: age at diagnosis (≤30, 31-49, 50-69 and ≥70), the lower age group being the reference class; alcohol consumption
(never, social and regular drinkers), never drinkers being the reference class, and smoking habits (smokers/non-smokers), non-smokers
being the reference class.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Linkage disequilibrium coefficient D' between the
three studied SNPs.
–––––––––––––––––––––––––––––––––––––––––––––––––
SNP P110S S112T E210A
–––––––––––––––––––––––––––––––––––––––––––––––––
P110S - 0.8992 0.9665
S112T - - 0.9696
E210A - - -
–––––––––––––––––––––––––––––––––––––––––––––––––
Table V. GSTA2 haplotype frequencies in Portuguese popu-






GSTA2 (P110; S112; E210)a 0.5713 0.5387
GSTA2 (P110; S112; A210)a NA 0.00140
GSTA2 (P110; T112; E210)a 0.3303 0.3679
GSTA2 (S110; S112; E210)a NA 0.003
GSTA2 (P110; T112; A210) 0.0567 0.0562
GSTA2 (S110; T112; E210) 0.0418 0.0328
–––––––––––––––––––––––––––––––––––––––––––––––––
aHaplotypes also identified by Tetlow et al (13).
–––––––––––––––––––––––––––––––––––––––––––––––––
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role of these haplotypes in breast cancer susceptibility do not
reveal any significant association with the disease (data not
show).
Discussion
There is a lack of data on the role of GSTA2 polymorphisms
in human cancers. The data published until now has been
mainly focused on GSTA2 genomic organization, its expression
in different tissues (31-33) and functional characterization of
the GSTA2 polymorphisms (12,13,17,34,35).
Several polymorphisms in GSTA2 gene were described by
Tetlow et al in three different ethnic populations. Some
functional studies developed to evaluate the protein activity
of variants generated by multiple polymorphisms, report in
all but one haplotype [GSTA2 (S110; S112; E210)] no
significant discrepancy in protein activity when compared
with the more frequent haplotype [GSTA2 (P110; S112;
E210)] (12,13,17). In fact, the variant form has a lower
activity towards the conjugation of several substrates, such as
Cumene hydroperoxide (12), suggesting that individuals with
the S110 variant may have an increased susceptibility to
disease related with oxidative stress. Additionally, the GSTA2
is also involved in the isomerization of Δ5-androstene-3,17-
dione, a precursor of several steroid hormones, such as
progesterone. The variant form of GSTA2 S110 also shows a
lower activity towards this substrate, suggesting that indivi-
duals carrying this variant might have lower levels of steroid
hormones. These studies structurally characterized the
polymorphisms of human glutathione S-transferase alpha
class, showing that S112T and E210A amino acid residues
are not in the active site. The change S112T is conservative
(both residues are polar non-charged) and did not show a
dramatic effect on protein structure, while E210A is non-
conservative (A residue is a small polar and E a large acidic
residue), although this residue position could have a slight
effect on protein function. Concerning the P110S it was
shown that the substitution of a hydrophobic residue, non-
polar (Pro), by a hydrophilic, uncharged polar residue (Ser),
might both reduce the rigidity of the active site related to the
loss of a structural residue, and increase hydrophilicity (12).
We performed a comprehensive study to analyze the
possible role of 3 common non-synonymous polymorphisms
(P110S; S112T; E210A) of GSTA2 gene in the genetic
susceptibility to breast cancer, which, to our knowledge, is the
first study relating breast cancer with these polymorphisms.
However, our results did not reveal any association of the
different GSTA2 polymorphisms evaluated and individual
susceptibility to breast cancer (Table III). These results
might be explained by the fact that the S112T and E210A
polymorphisms do not lead to a significant decrease in the
enzyme catalytic activity, and the polymorphism associated
with changes in catalytic activity (GSTA2 P110S), is only
observed in heterozygosity, and with a frequency lower than
10% in both populations (cases and controls) (Table III).
Regarding the molecular-epidemiological studies concerning
GSTA2 polymorphisms, no association between the GSTA2
(S112T) polymorphism and the risk of colorectal cancer,
malignant pleural mesothelioma (29,30) and prostate cancer
(17) was described, but the variant allele of this poly-
morphism seems to be associated with an increased risk of
lung cancer (16). Additionally, our study reveals that all
SNPs studied are in linkage disequilibrium. Through the
combination of the different allelic variants of GSTA2 non-
synonymous polymorphisms, we obtained six different
haplotypes in our populations (see Table V), which is in
agreement with the data reported in previous studies (12,13).
However, the results showed consistent differences on haplo-
type frequencies in other populations (12,13), that could be
explained based on the basis of ethnic differences between
populations.
Recent data from cancer studies have linked aberrant
expression of GST isozymes with the development and
expression of resistance to a variety of chemicals, especially
the ones used as anticancer therapies. Studies in tumor
tissues and chemotherapeutic-resistant tumor cell lines have
shown overexpression of these enzymes (9,36). Further-
more, studies in normal and cancer human breast tissue,
showed that in most cases, the average level of GSTs was
substantially elevated in the cancer tissues when compared
with normal tissue, providing a plausible mechanism for the
variable response to treatment (33).
Even though our data suggest that GSTA2 polymorphisms
are not associated with individual susceptibility to breast
cancer risk, we cannot exclude that other SNPs in other genes
associated with the detoxification might be involved in
susceptibility to breast cancer. Additionally, we also cannot
exclude that these polymorphisms might be associated with
other aspects of oncologic disease such as drug resistance/
patient survival, but further studies are required to evaluate
this effect.
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